Alle patienterne fik konstante methotrexat doser (median 15 mg/ uge) i 6 måneder før inklusionen og skulle fortsætte med konstante doser under hele undersøgelsen.
All patients were on stable methotrexate doses (median 15 mg/ wk) for 6 months prior to enrolment and were to remain on stable doses throughout the study.